Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV-related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines. However, cost-effectiveness studies regarding this treatment are rare. The objective of this study was to estimate the cost-effectiveness of NA treatment after resection in HBV-related HCC patients with compensated cirrhosis. A Markov model was constructed to simulate HBV-related HCC patients with compensated cirrhosis and detectable HBV DNA, with or without NA treatment after resection, followed up over their lifetime. Costs, life expectancy, qualityadjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER) were calculated for each strategy from the societal perspective. The parameters of the model were derived from published studies, government documents, and our surveys. Sensitivity analyses were used to explore the impact of parameters on the uncertainty of the results. NA treatment produced 4.22 QALYs, costing $39,898, while non-NA treatment achieved 2.80 QALYs, costing $16,048. The ICER of NA treatment versus non-NA treatment was $16,848/QALY, which was between 2 and 3 times gross domestic product per capita and was therefore deemed cost-effective. Probabilistic sensitivity analysis confirmed that NA treatment was cost-effective, with a probability of 0.852. Conclusion: NA treatment after liver resection was likely cost-effective in HBVrelated HCC patients with compensated cirrhosis. (HEPATOLOGY 2018; 68:1476-1486).
H epatocellular carcinoma (HCC) has a high incidence and mortality worldwide.
(1) It was estimated that there were about 782,500 new HCC cases in 2012, making it the sixth most frequently diagnosed cancer. Mortality from HCC was ranked second among causes of cancer deaths, responsible for nearly 745,500 deaths in 2012. (2) Chinese patients accounted for about 50% of the total new HCC cases and HCC-related mortalities. (2) Risk factors for HCC include chronic infectious hepatitis (types B and C), alcoholic cirrhosis, and aflatoxin exposure. In China, a high-prevalence area of hepatitis B, >80% of HCC cases are associated with hepatitis B virus (HBV) infection. (3) The majority of these patients (80%-95%) have cirrhosis at the time of HCC diagnosis. (4) The outcomes of HCC treatment are unsatisfactory even in early stages, when patients can receive potentially curative treatments. The 5-year survival after potentially curative resection may be >70%, but it is hampered by recurrence rates of >70%. Antiviral treatment with nucleos(t)ide analogues (NAs) in chronic Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ETV, entecavir; GDP, gross domestic product; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; NA, nucleos(t)ide analogue; QALY, quality-adjusted life-year; RR, relative risk; TDF, tenofovir.
hepatitis B patients has been demonstrated to reduce HBV replication; to prevent disease progression to compensated cirrhosis, decompensated cirrhosis, and HCC; and therefore to prolong survival. (5) Increasing numbers of studies demonstrate the benefits of NA treatment in HBV-related HCC after curative resection. (6) (7) (8) (9) A retrospective cohort study from Taiwan's National Health Insurance Research Database examined the association between use of NAs and outcomes of patients with HBV-related HCC after curative resection. (6) The study confirmed that use of NAs was associated with a lower risk of HCC recurrence and mortality. Therefore, NA therapy is recommended for HBV-related HCC according to guidelines from Europe, the Asia-Pacific region, and China. (10) (11) (12) (13) NA treatment in patients with HBV-related HCC is thought, firstly, to suppress HBV replication, induce the stabilization of HBV-induced liver disease, and prevent disease progression and, secondly, to reduce the risk of HCC recurrence after potentially curative HCC therapies. Stabilizing the HBV-induced liver disease can also be regarded as a prerequisite for the safe and effective application of HCC treatments. (13) Chinese guidelines for chronic hepatitis B and hepatitis B/C virus-related HCC recommend that adjuvant NA treatment be given if the HCC is HBV-related and HBV DNA is detectable. (10, 11) If the patient has underlying cirrhosis, long-term treatment with entecavir (ETV) or tenofovir (TDF) is preferred. (10, 11) Cost-effectiveness analyses of NA in HBV-related HCC are rare. NA treatment requires relatively longterm treatment to show effectiveness at preserving liver function, reducing recurrence, and improving survival. However, HCC patients have poor survival, impairing the benefits of NA treatment. Furthermore, NA treatment increases the total cost burden of treatment. Whether NA treatment is cost-effective in this population remains unclear. Therefore, we performed a preliminary cost-effectiveness analysis of NA treatment after resection in HBV-related HCC patients with compensated cirrhosis, who are most likely to gain from NA treatment and account for a large proportion of HCC patients in China. It is estimated that there were 466,100 new HCC cases in China in 2015. (14) Of these cases, >80% were associated with HBV infection, 80%-95% had cirrhosis at the time of diagnosis, and 25%-40% were eligible for resection. (4, 15, 16) As many as 100,000 new cases per year in China meet the criteria that this study aimed to explore.
Materials and Methods

MARKOV MODEL
A cost-effectiveness analysis was performed from the societal perspective, based on a Markov model using TreeAge Pro 2012 (TreeAge Software, Inc., MA) (Fig. 1 ). In the model, patients entered a Markov process after resection, with or without initiation of NA treatment, and transitioned between five discrete states: compensated cirrhosis, decompensated cirrhosis, resectable recurrent HCC, unresectable recurrent HCC, and death. The model simulated a hypothetical cohort of 100,000 cases of 50-year-old HBV-related HCC patients with compensated cirrhosis and detectable HBV DNA. Patients were modeled as having undergone two alternative strategies: NA treatment and non-NA treatment. All patients received lifelong NA treatment or not, in addition to conventional surveillance and treatment of HCC after resection. The model was terminated when >99% of the cohort died, with a cycle length of 1 year and application of halfcycle correction.
NA treatment included first-line NA regimens (ETV and TDF), follow-up procedures, and laboratory examinations recommended by Chinese guidelines for chronic hepatitis B.
(10) The second-line NAs lamivudine, adefovir, and telbivudine were not considered
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because they are not recommended by the guidelines for this population. Conventional surveillance and treatment of HCC after resection followed the recommendation of the Chinese Ministry of Health. (4) The definitions of compensated cirrhosis and decompensated cirrhosis were based on the Child-Pugh score. Child-Pugh class A is compensated cirrhosis, and Child-Pugh classes B and C are decompensated cirrhosis. The definitions of resectable recurrent HCC and unresectable recurrent HCC were based on the Barcelona Clinic Liver Cancer (BCLC) system. Resectable recurrent HCC was defined as BCLC stages 0 and A. Unresectable recurrent HCC was BCLC stages B, C, and D. A resectable recurrent HCC patient could receive liver resection only once more. Liver transplantation was not considered because the proportion of liver transplantations was extremely small relative to the large HCC population in China.
MODEL PARAMETERS
Literature reviews were conducted to derive values for the transition probabilities, utilities, and costs. Basic values, ranges, and distributions of parameters used in the model are described below and summarized in Table 1 . Details on parameters used to derive transition probabilities between two states and related references are found in the Supporting Information.
ANNUAL TRANSITION PROBABILITIES
The annual transition estimates were governed by disease progression in non-NA treatment and NA treatment. Disease progression estimates in non-NA treatment were derived from cohort studies and metaanalyses. When accumulative rates were reported, they were transformed into annual probabilities by applying the declining exponential approximation of life expectancy approach. (32) Disease progression estimates in NA treatment, representing the effectiveness of NA treatment, were expressed as relative risk (RR) of NA versus non-NA.
There is a lack of studies regarding the risk of progression from compensated cirrhosis to decompensated cirrhosis after HCC resection. Therefore, studies on the progression to decompensated cirrhosis in non-HCC patients with cirrhosis were used. The sample sizes and progression rates in relative studies were extracted and pooled. The pooled median of annual transitions of progression to decompensation cirrhosis was 0.07. This figure was used as the base-case value of disease progression from compensated cirrhosis to decompensated cirrhosis in non-NA (Supporting Table S1 ). The range was estimated by the maximum and minimum values in these studies. The RR of NA versus non-NA from compensated cirrhosis to decompensated cirrhosis was conservatively estimated at 0. study of Liaw et al., which was the only randomized controlled trial comparing the effectiveness of NA treatment with placebo in preventing disease progression in patients with cirrhosis. (5) It was a conservative estimate because the progression of compensated cirrhosis in this study included transition not only to decompensated cirrhosis but also to HCC and death and the drug for treatment was lamivudine instead of ETV or TDF. The effectiveness of lamivudine in preventing disease progression to decompensated cirrhosis should be worse than the effectiveness of ETV or TDF.
Recurrence and mortality rates after resection in patients with compensated cirrhosis were derived from meta-analyses. We retrieved five meta-analyses comparing NA treatment with non-NA treatment after curative treatment for patients with HBV-related HCC (Supporting Table S2 ). (7, 8, 17, 33, 34) One of these meta-analyses pooled the accumulative recurrence rate and survival after curative treatment. (17) Based on this study, the base-case values of recurrence rate and mortality in compensated cirrhosis after resection were estimated at 0.15 and 0.09, respectively. The ranges were estimated by the maximum and minimum values in studies enrolled in the meta-analyses. The RR of NA versus non-NA for HCC recurrence and mortality after resection in compensated cirrhosis used the worst results from the five meta-analyses for conservative estimation, which were 0.75 (95% CI 0.6-0.9) and 0.46 (95% CI 0.29-0.73), respectively. (17, 33) Given concerns as to whether antiviral therapy after curative resection of HBV-related HCC would prevent HCC recurrence, we expanded the upper limit of the 95% CI of RR for recurrence from 0.9 to 1, in which the value means that antiviral therapy would not reduce recurrence rates.
The HCC recurrence rate after resection in patients with decompensated cirrhosis was assumed to be the same as the recurrence rate in compensated cirrhosis, considering that HCC recurrence after resection relies more on the stage of HCC than on the disease underlying HCC. Mortality after resection in patients with decompensated cirrhosis was referred to as the mortality of non-HCC patients with decompensated cirrhosis. The outcomes of resectable and unresectable recurrent HCC after re-resection were derived from studies of repeat liver resection.
COSTS
This study considered only direct costs, including direct medical costs and direct nonmedical costs. Indirect costs due to productivity loss were not included. Direct medical costs included outpatient expenditures, inpatient expenditures, and the expenditures for medicines selfpurchased in retail pharmacies. Direct nonmedical costs included family travel expenses and extra health product expenses. The model assumed that each disease state had an associated cost of care. Disease state costs were derived from our survey covered 27 hospitals in 12 cities of six provinces in 2009. (29) The survey enrolled 4,718 patients to investigate the costs of various types of HBV-related diseases. The costs of states were calculated by per capita outpatient expenditure, inpatient expenditure, selfmedication expenditure, and annual outpatient and inpatient visit frequencies. The annual cost arising from NA treatment was estimated at $2,268, according to the daily dose prices of regimens (the government contract prices for ETV and TDF were about $5 and $6 per day, respectively) and to follow-up procedures recommended by the Chinese chronic hepatitis B management guidelines. (10) The costs of states may have overlapped with the cost of NA treatment because the costs of states included outpatient expenditures and inpatient expenditures. According to our survey, the average numbers of annual visits, outpatient and inpatient, were 3.4 and 2, respectively. (29) Prescription management regulations issued by the Chinese Ministry of Health limited outpatient prescriptions to no more than a 7-day supply. Therefore, the overlap between the cost of NA treatment and the costs of disease states might have been limited. This could be resolved in sensitivity analyses by setting a broad range. The cost of repeat resection for resectable recurrent HCC was $6,421, based on expert advice from three hospitals in different provinces. Due to the huge differences in costs between various regions in China, a wide range (650%) was given in sensitivity analyses to cover uncertainties. Costs were converted from Chinese dollars to US dollars at an average exchange rate of 6.23 in 2015.
UTILITY SCORES AND THE DISCOUNT RATE
Constant utility scores were assigned to different disease states based on published reports. There were few studies of utility scores of the different stages of HCC. Therefore, relevant cost-effectiveness studies were also referenced. In order to cover the majority of reported data, a wide range was given to each utility score. The discount rate was 5%, based on China's Guidelines for Pharmacoeconomic Evaluations, and was adjusted between 0% and 10%. (31) 
COST-EFFECTIVENESS ANALYSIS
The expected costs, life expectancy, and qualityadjusted life-years (QALYs) discounted to 2015 were obtained and compared between the two strategies by running the model. Cost-effectiveness estimates were derived based on the incremental cost per QALY gained, defined as the incremental cost-effectiveness ratio (ICER), and assessed according the recommendation of the World Health Organization. A strategy would be highly cost-effective when the ICER was at <1 times the gross domestic product (GDP) per capita. It would be cost-effective for 1-3 times the GDP per capita and cost-ineffective for >3 times the GDP per capita. (35) The GDP per capita of China in 2015 was $8,024. (36) 
SENSITIVITY ANALYSES
A series of sensitivity analyses was performed to evaluate the uncertainty of parameter estimates and the robustness of the model. Univariate sensitivity analyses were done for all parameters within their respective ranges, shown in Table 1 , to show how each parameter impacted the results and to identify the main influential parameters. The results were expressed as tornado charts. Threshold analyses were followed to identify the thresholds of the main influential parameters for the ICER over 3 times the GDP per capita. A probabilistic sensitivity analysis (second-order Monte Carlo simulation) was further conducted to estimate the simultaneous impact of parameter uncertainty on the analysis. Each rate, cost, and utility was placed in the model with its respective distribution ( Table 1 ). The results of 1,000 iterations were plotted as costeffectiveness acceptability curves.
Results
BASE-CASE RESULTS
The model simulated the impact of NA treatment on preventing disease progression and prolonging survival in the target population ( Fig. 2A) . At various time points after resection, the NA treatment cohort maintained more patients in early disease states and more survivors than did the non-NA treatment cohort. A total of 11,531 patients were still alive after 15 years in the NA treatment cohort based on 100,000 population, while almost all (>99%) of the non-NA treatment cohort had died by this time point. The model also simulated the impact of NA treatment on the total cost compared with non-NA treatment (Fig. 2B) . The increase in total cost was due not only to the increase in the cost of additional NA treatment itself but also to the increase in the health care costs of disease states resulting from increased numbers of survivors in the NA treatment cohort. After lifetime calculation, NA treatment could gain an average 2.07 years of life expectancy compared to non-NA treatment, which produced 1.42 QALYs per capita after adjusting the utilities of disease states (Table 2) . Together with the additional total cost per capita ($23,865), the ICER of NA treatment versus non-NA treatment was $16,848 per QALY gained. This was slightly higher than 2 times the GDP per capita ($16,048) but far lower than 3 times the GDP per capita ($24,072).
SENSITIVITY ANALYSES RESULTS
Univariate sensitivity analyses found that the RR of NA versus non-NA for HCC recurrence in patients with compensated cirrhosis and the utility of compensated cirrhosis were the two main influential parameters (Fig. 3) . With their changes in the respective estimated ranges, the ICER could exceed 3 times the GDP per capita. The increment of the first parameter, RR of NA versus non-NA for HCC recurrence in compensated cirrhosis, was responsible for the increment of ICERs. Conversely, the ICER values would increase if the utility of compensated cirrhosis decreased. Threshold analyses for these two parameters demonstrated that their thresholds for the ICER over 3 times the GDP per capita were 0.99 and 0.51, respectively.
The result of probabilistic sensitivity analysis showed the relationship between the probability of costeffective of NA treatment versus non-NA treatment and the willingness to pay (Fig. 4) . With the increment of willingness to pay beyond the 1 times the GDP per capita, the probability of being cost-effective for the NA treatment strategy would increase steadily. This probability of NA treatment would be higher than the probability of non-NA treatment when willingness to pay above $19,000 was accepted and reached 0.852 when the willingness to pay was 3 times the GDP per capita, which was the predefined threshold of being cost-effective.
Discussion
The treatment of HCC is a challenge due to high recurrence rates and mortality, despite the fact that there are now many treatment approaches, such as liver resection, radiofrequency ablation, transcatheter arterial chemoembolization, and sorafenib. NA treatment sheds some light on the treatment of HBV-related HCC and is recommended by numerous guidelines. The role of NA treatment varies by stage of HBVrelated HCC. In patients at an early stage of disease, NA treatment can prevent disease progression, reduce recurrence, and prolong survival. In patients at intermediate and advanced stages, especially those receiving transcatheter arterial chemoembolization and radiotherapy, NA treatment can prevent HBV reactivation and reduce the risk of death due to liver failure. (11) The present study targeted HBV-related HCC patients with compensated cirrhosis in early stages who were more likely to benefit from NA treatment and who accounted for a large proportion of patients in China. The model projected that NA treatment could gain an average 2.07 years of life expectancy compared with non-NA treatment. The ICER was $16,848 per QALY gained, which was slightly higher than 2 times the GDP per capita but far lower than 3 times the GDP per capita. A series of sensitivity analyses was performed to overcome the impact of the uncertainty of parameter estimates on the model results. The two main influential parameters identified by univariate sensitivity analyses, the RR of NA versus non-NA for HCC recurrence in compensated cirrhosis and the utility of compensated cirrhosis, were followed by threshold analysis. The threshold analysis showed that the ICER would be more than 3 times the GDP per capita when the value of the former parameter was >0.99, revealing that NA treatment would be costeffective if it achieved only a small effect on reducing HCC recurrence. The threshold of the utility of compensated cirrhosis, another main influential parameter, 
FIG. 3.
Tornado graph of univariate sensitivity analyses. A horizontal bar was generated for each parameter analyzed. The width of the bar indicates the potential effect of the associated parameter on the ICER when the parameter is changed within its range (as shown in Table 1 ). The dark gray part of each bar indicates high-range input values, while the light gray part indicates low-range values. The solid vertical line represents the ICER under the base-case scenario. Abbreviations: CC, compensated cirrhosis; DC, decompensated cirrhosis; P, annual transition probability.
FIG. 4.
Cost-effectiveness acceptability curves of NA treatment versus non-NA treatment. When the threshold of willingness to pay was up to 3 times GDP per capita, the probability of cost-effectiveness of NA treatment reached 0.852. was 0.51 for the ICER over 3 times the GDP per capita. In most studies, the utility of compensated cirrhosis was more than 0.6 because compensated cirrhosis was still in the early stage of liver disease when patients were generally asymptomatic. (30, 32, 37) The threshold analysis showed that the change of most influential parameters had little effect on the results. The result of probabilistic sensitivity analysis also confirmed that NA treatment had a high probability of costeffectiveness. This suggested that NA treatment after resection in HBV-related HCC with compensated cirrhosis was likely cost-effective, and the results were robust.
We conducted a cost-effectiveness analysis to account for NA treatment in HBV-related HCC patients. Previous studies mainly focused on costeffectiveness of conventional treatments in HCC patients or antiviral treatment in chronic hepatitis B patients. One study assessed the cost-effectiveness of adjuvant antiviral treatment after resection of HCC, but it focused on hepatitis C virus-related HCC and the treatment regimen was interferon. (38) In this study, we took pains to ensure the reliability of our results. First, the model structure was communicated repeatedly with clinical experts to align with the clinical practices to the greatest extent possible. In HCC patients, the prediction of prognosis was more complex because not only tumor stage but also underlying liver function affected prognosis. The BCLC staging system is the only system that considers both tumor stage and liver function, that stratifies patients into separate prognosis categories, and that links staging stratification with treatment choices. BCLC is recommended by the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, the European Organization for Research and Treatment of Cancer, and the European Society for Medical Oncology-Environment and Social Development Organization. (39) (40) (41) Defining the states by the BCLC staging system ensured the patients' homogeneity in each state, which meant that patients in the same state had similar treatment choices and outcomes. Second, the method of RR compared to non-NA treatment was used to estimate the effectiveness of NA treatment. If the conventional method of data acquisition by systematic review of the literature was used to obtain the base-case values and ranges of effectiveness of NA treatment and non-NA treatment, the ranges of effectiveness of two strategies, such as HCC recurrence and mortality, might overlap. Although, considered separately, the ranges are realistic, there might be a logical error in sensitivity analyses. This is because HCC recurrence and mortality after resection in NA treatment are unlikely to be worse than in non-NA treatment. The method of RR avoided this logical error. Finally, conservative estimation was made as much as possible to avoid overestimating the benefits of NA treatment. In all of the meta-analyses used to estimate the RR of NA treatment versus non-NA treatment, NA regimens included mixes of lamivudine, adefovir, and telbivudine, rather than looking at ETV or TDF only. This impaired the benefits of NA treatment. In this study, fibrotic regression of NA treatment in patients with cirrhosis was not considered, further limiting the benefits of NA treatment.
Our study had two main limitations. First, all patients in the model were assumed to receive lifelong NA treatment according to the recommendation of the guidelines without considering compliance to NA treatment. In the treatment of chronic hepatitis B patients with NA therapy, up to 30% of virologic breakthrough observed in clinical trials was related to medication noncompliance. (42) It was reported that only about 50% patients with chronic hepatitis B in the United States had good compliance to NAs. (43) In China, it is estimated that the compliance rate did not exceed 80% even with reimbursement for chronic hepatitis B patients. (44) There are few studies regarding the compliance with NA treatment in HBV-related HCC patients and the impact of noncompliance on the outcomes of HBV-related HCC patients. However, in theory, noncompliance may lead to virologic breakthrough and may weaken the benefits of NA treatment. Second, we did not consider the resistance to and adverse events of ETV and TDF. This might overestimate the benefits of NA treatment. However, resistance to and adverse events of ETV and TDF are rare. Limited survival of HCC patients further reduced the incidence of resistance and adverse events.
